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Introduction: Invasive mucinous adenocarcinoma is a unique histo-
logic subtype of lung cancer, and our knowledge of its genetic and clini-
cal characteristics is rapidly evolving. Here, we present next- generation 
sequencing analysis of nucleotide variant and fusion events along with 
clinical follow-up in a series of lung mucinous adenocarcinoma.
Methods: We collected 72 mucinous adenocarcinomas from the 
United States and Korea. All had been previously assessed for KRAS 
and EGFR mutations. For KRAS wild-type cases (n = 30), we per-
formed deep targeted next-generation sequencing for gene fusions and 
nucleotide variants and correlated survival and other clinical features.
Results: As expected, KRAS mutations were the most common altera-
tion found (63% of cases); however, the distribution of nucleotide posi-
tion alterations was more similar to that observed in gastrointestinal 
tumors than other lung tumors. Within the KRAS-negative cases, we 
found numerous potentially targetable gene fusions and mutations, 
including CD74-NRG1, VAMP2-NRG1, TRIM4-BRAF, TPM3-NTRK1, 
and EML4-ALK gene fusions and ERBB2, BRAF, and PIK3CA muta-
tions. Unexpectedly, we found only two cases with TP53 mutation, 
which is much lower than observed in lung adenocarcinomas in gen-
eral. The overall mutation burden was low in histologically confirmed 
mucinous adenocarcinomas from the public The Cancer Genome 
Atlas exome data set, regardless of smoking history, suggesting a link 
between TP53 status and mutation burden in mucinous tumors. There 
was no significant difference for recurrence-free survival between stage-
matched mucinous and nonmucinous adenocarcinomas. It was notable 
that all recurrence sites were in the lungs for completely resected cases.
Conclusions: Our data suggest that mucinous adenocarcinoma is 
typified by (1) frequent KRAS mutations and a growing list of gene 
fusions, but rare TP53 mutations, (2) a low mutation burden overall, 
and (3) a recurrence-free survival similar to stage-matched nonmuci-
nous tumors, with recurrences limited to the lungs.
Key Words: Lung, Adenocarcinoma, Mucinous, Mutation, Gene 
fusion, Targeted therapy.
(J Thorac Oncol. 2015;10: 1156–1162)
Lung cancer is a leading cause of cancer-related mortal-ity,1 and adenocarcinoma is its most common histologic 
type.2 Invasive mucinous adenocarcinoma, formerly known 
as mucinous bronchioloalveolar carcinoma, is a distinct vari-
ant of adenocarcinoma of the lung, accounting for approxi-
mately 5% of lung adenocarcinomas.2 Its histology is unique 
among the primary lung cancers and is typified by a columnar 
or goblet cell structure with basally located nuclei and abun-
dant intracytoplasmic mucin. Invasive mucinous adenocarci-
noma is well known as having a distinct clinical presentation 
and genetic profile compared with nonmucinous adenocar-
cinoma.2–6 Patients with invasive mucinous adenocarcinoma 
frequently present with a pneumonia-like pattern and with 
multifocal and multilobar lesions.3 There are conflicting data 
about the relative prognosis of patients with mucinous adeno-
carcinoma.7,8 In terms of genetic alterations, invasive muci-
nous adenocarcinoma shows a strong correlation with KRAS 
mutations.4–6
However, comprehensive molecular or clinical stud-
ies on invasive mucinous adenocarcinoma have been lim-
ited so far because the histology is relatively rare compared 
with other subtypes. Although a comprehensive molecu-
lar profiling of lung adenocarcinomas from The Cancer 
Genome Atlas (TCGA) has been published,9 a detailed 
analysis of this subtype is warranted. Recently, CD74-
NRG1 fusions have been discovered in lung mucinous 
adenocarcinoma,10–12 showing that these tumors are likely 
genetically unique.
To address the genetic and survival characteristics of 
invasive mucinous adenocarcinoma of the lung, we performed 
targeted next-generation sequencing for gene fusions and 
mutations, analyzed TCGA lung adenocarcinoma data, and 
investigated clinical features in this subtype when compared 
with nonmucinous adenocarcinomas.
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MATERIALS AND METHODS
Study Population
We collected a total of 83 mucinous adenocarcinomas from 
Massachusetts General Hospital, Boston, Massachusetts (n = 35) 
and Yonsei University Severance Hospital, Seoul, Korea (n = 48) 
(Supplementary Fig. 1, Supplemental Digital Content, http://links.
lww.com/JTO/A842) under Institutional Review Board approval. 
All samples were resected specimens and formalin-fixed and paraf-
fin-embedded. Two pulmonary pathologists (H.S.S. and M.M.-K.) 
reviewed the slides and confirmed the diagnosis based on the 
International Association for the Study of Lung Cancer/American 
Thoracic Society/European Respiratory Society (IASLC/ATS/
ERS) classification.2 All clinical information, such as age, gender, 
smoking status, and stage, were obtained from medical records. We 
also collected a total of 269 nonmucinous adenocarcinomas from 
Massachusetts General Hospital (n = 63) and Yonsei University 
Severance Hospital (n = 206) as a control group for survival analysis. 
All patients underwent surgical resection for curative intent. TCGA 
data for lung adenocarcinomas (n = 230) were obtained from the 
public on-line cBioPortal database.9,13,14 Histologic review for each 
case was done using Digital Slide Archive in the cBioPortal.
SNaPshot Genotyping
Multiplexed targeted genotyping was done using the 
SNaPshot method as previously described.15,16 The SNaPshot 
platform from Applied Biosystems (Life Technologies/Applied 
Biosystems, Foster City, CA) consisted of multiplexed poly-
merase chain reaction (PCR) and single-base extension reac-
tions that generate fluorescent labeled probes designed to 
interrogate hot-spot mutation sites. The SNaPshot products 
were then resolved and analyzed using capillary electrophoresis.
Sanger Sequencing for EGFR 
and KRAS Mutation
A representative formalin-fixed, paraffin-embedded block 
containing at least 50% viable tumor was selected for each sam-
ple. After proteinase K digestion, DNA was extracted using a 
DNeasy DNA isolation kits (Qiagen, Valencia, CA) according 
to the manufacturer’s instructions. Direct DNA sequencing of 
exons 18 through 21 of the EGFR gene and codons 12 and 13 of 
the KRAS gene was performed as previously described.17,18
Anchored Multiplex PCR and  Next-
Generation Sequencing
To detect gene fusions and mutations, we used a gene 
enrichment method, anchored multiplex PCR, to perform 
next-generation sequencing using MiSeq (Illumina, San 
Diego, CA) platform as previously described in detail.19 
Total nucleic acid containing total RNA and genomic DNA 
were extracted from formalin-fixed paraffin-embedded tis-
sue, using the Agencourt FormaPure Kit (Beckman Coulter, 
Indianapolis, IN). We used at least 50 ng of total nucleic acid 
for fusion analysis and 200 ng of genomic DNA for mutation 
analysis. The genes covered in each primer panel are shown in 
Supplementary Table 1 (Supplemental Digital Content, http://
links.lww.com/JTO/A842).
Immunohistochemisty
Formalin-fixed and paraffin-embedded tissues were sec-
tioned with a thickness of 4 μm and stained with antibody 
for p53 (mouse monoclonal, clone DO-7, ready-to-use, Leica 
Biosystems, United Kingdom) using Leica Bond 6 automated 
stainer according to the manufacturer’s protocol. p53 immu-
nohistochemistry was considered to be abnormal when the 
expression was present in 50% or greater of the tumor cells or 
was completely negative.
Statistical Analysis
Relationships between clinicopathologic parameters were 
evaluated using the chi-square test. Student’s t test was used to 
compare means between two independent groups. We planned a 
survival comparison study of mucinous cases and nonmucinous 
cases (controls) with four controls per case. Prior data indicated 
that the overall 5-year survival rate among controls is 60%. If 
the survival rate among mucinous cases is 80%, we needed to 
study at least 52 patients with mucinous adenocarcinoma and 
208 control patients to be able to reject the null hypothesis that 
the survival rates for case and controls are equal with probabil-
ity (power) 0.8. This sample size was calculated by Power and 
Sample Size Calculations (Version 3.1.2; Vanderbilt University, 
Nashville, TN). The disease-free survival and overall survival 
were evaluated using the Kaplan–Meier method, and statistical 
differences in survival times were determined using the log-
rank test. Data analysis was conducted using SPSS v.17 (SPSS, 
Chicago, IL) or Prism 6 (GraphPad Software, San Diego, CA). 
Significance was defined as p value less than 0.05.
RESULTS
We identified 83 cases of mucinous adenocarcinoma, 
including 81 invasive mucinous adenocarcinomas, one muci-
nous adenocarcinoma in situ, and one minimally invasive 
mucinous adenocarcinoma (all defined using the IASLC/
ATS/ERS criteria) and 269 nonmucinous cases from the case 
records of the Massachusetts General Hospital and the Yonsei 
University Severance Hospital (detailed information accord-
ing to the institutions in Supplementary Table 2, Supplemental 
Digital Content, http://links.lww.com/JTO/A842). There were 
no significant differences between patients with mucinous ade-
nocarcinoma and those with nonmucinous adenocarcinoma 
with respect to age, sex, smoking status, or stage (Table 1). Of 
83 patients with mucinous adenocarcinoma, KRAS genotyp-
ing was previously done for 72 cases. For KRAS wild-type 
cases (n = 30), we performed targeted deep sequencing for 
gene fusions and mutations using the anchored multiplex PCR 
method. We found driver mutations and fusions in 16 of the 30 
cases (Fig. 1), including three cases with KRAS mutation not 
found with the prior less-sensitive methods (Supplementary 
Tables 3 and 4, Supplemental Digital Content, http://links.lww.
com/JTO/A842). There was no significant difference between 
KRAS mutated (n = 45) and KRAS wild-type (n = 27) groups 
in terms of age, gender, smoking status, and stage (Table 2).
We identified gene fusions in nine cases, including four 
with a CD74-NRG1 fusion, two with an EML4-ALK fusion, 
one each with a VAMP2-NRG1 fusion, a TRIM4-BRAF fusion, 
and a TPM3-NTRK1 fusion. We confirmed novel fusions using 
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reverse-transcriptase PCR (data not shown). The CD74-NRG1 
fusion and VAMP2-NRG1 fusion seem to be generated by 
interchromosomal translocation (Supplementary Figs. 2 and 3, 
Supplemental Digital Content, http://links.lww.com/JTO/A842) 
and retain an intact epidermal growth factor-like domain. The 
TRIM4-BRAF fusion and TPM3-NTRK1 fusion seem to be gen-
erated by intrachromosomal tandem duplication and paracentric 
inversion, respectively (Supplementary Fig. 4, Supplemental 
Digital Content, http://links.lww.com/JTO/A842). Both BRAF 
and NTRK1 retain an intact kinase domain. There were no sig-
nificant difference in gene fusion status according to smoking 
history (p = 0.194), although six out of nine fusion-positive cases 
were identified in never smokers. There was no statistical differ-
ence in molecular profile between the U.S. and Korean patients 
(Supplementary Table 5, Supplemental Digital Content, http://
links.lww.com/JTO/A842).
We also identified mutations in eight of the cases, includ-
ing three cases with KRAS mutation. Additional mutations 
included two with ERBB2 mutation (exon 20 AYVM inser-
tion), and one each with BRAF mutation (V600E), PIK3CA 
mutation (E542K), and TP53 mutation (H197D) (Fig. 1). Of 
30 cases tested by next-generation sequencing, apart from 
TP53, these mutations and fusions were mutually exclusive.
The distribution of mutations revealed that 63% of all 72 
cases had KRAS mutations, which as expected were the most 
common variant observed (Fig. 2A). NRG1 fusions were second 
most common, accounting for 7%. When all fusion cases were 
combined, they accounted for 13% of all cases in our cohort.
The distribution of KRAS amino acid changes in the 
mucinous tumors was examined and was found to be distinct 
from the KRAS mutation profile in lung adenocarcinoma in 
general as well as the profile of TCGA lung adenocarcinoma 
cases. G12D (42%) and G12V (31%) were the most common 
variants observed in mucinous tumors (Fig. 2B), whereas G12C 
was the most common in lung adenocarcinoma.20 Interestingly, 
this pattern of KRAS mutations more resembles the mutational 
pattern seen in colorectal or pancreatobiliary tumors.20
A total of 50 cases were examined for TP53 mutation by 
next-generation sequencing, revealing only two TP53 muta-
tions (Fig. 1; Supplementary Fig. 5, Supplemental Digital 
Content, http://links.lww.com/JTO/A842). Because this rate 
of TP53 mutation was surprisingly low, we randomly analyzed 
a subset of tumors with immunohistochemistry for p53 and 
found 10 TP53 wild-type cases to be weak and focal staining 
compared with a positive control (TP53 mutated case) show-
ing the expected diffuse and strong staining (Supplementary 
Fig. 6, Supplemental Digital Content, http://links.lww.com/
JTO/A842). We attempted to confirm the low TP53 mutation 
rate in mucinous tumors in another data set and identified 12 
TABLE 1.  Clinical Characteristics of All Patients Enrolled in 
This Study
Histology
Mucinous 
(n = 83)
Nonmucinous 
(n = 269) p
Mean age (range) 62.2 (36–90) 62.7 (34–85) 0.743
Gender
  Male 36 (43.4) 130 (48.3%) 0.429
  Female 47 (56.6) 139 (51.7%)
Smoking status
  Never 39 (47.0) 137 (50.9) 0.530
  Ever 44 (53.0) 132 (49.1)
Stage
  I 55 (66.3) 192 (71.4) 0.063
  II 19 (22.9) 51 (19.0)
  III 7 (8.4) 26 (9.7)
  IV 2 (2.4) 0 (0.0)
FIGURE 1.  Mutation distribution for 30 mucinous 
adenocarcinomas that underwent NGS. All 30 cases 
were previously determined to be KRAS wild type 
by targeted methodology. NGS, next generation 
sequencing.
TABLE 2.  Clinical Characteristics of Patients with Mucinous 
Adenocarcinoma according to KRAS Status
Factors
Total  
(n = 72)
KRAS Mutant 
(n = 45)a
KRAS Wild 
(n = 27)a p
Mean age (range) 63.4 (37–90) 63.3 (37–90) 63.6 (41–84) 0.129
Sex
  Male 30 (41.7) 18 (40.0) 12 (44.4) 0.711
  Female 42 (58.3) 27 (60.0) 15 (55.6)
Smoking status
  Never 33 (45.8) 21 (46.7) 12 (44.4) 0.855
  Ever 39 (54.2) 24 (53.3) 15 (55.6)
Stage
  I 45 (63.4) 30 (66.7) 15 (57.7) 0.889
  II 17 (23.9) 10 (22.2) 7 (26.9)
  III 7 (9.9) 4 (8.9) 3 (11.5)
  IV 2 (2.8) 1 (2.2) 1 (3.8)
aThe KRAS status was determined by next-generation sequencing.
Copyright © 2015 by the International Association for the Study of Lung Cancer
1159Copyright © 2015 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 10, Number 8, August 2015 Invasive Mucinous Adenocarcinoma of the Lung
invasive mucinous adenocarcinomas out of 230 lung can-
cers from the public TCGA lung adenocarcinoma Digital 
Slide Archive (Supplementary Table 6, Supplemental Digital 
Content, http://links.lww.com/JTO/A842). Of the 12 cases, 
nine cases (75%) harbored KRAS mutation, one case had an 
ALK fusion, and one case had a RET fusion (Supplementary 
Table 6, Supplemental Digital Content, http://links.lww.com/
JTO/A842), whereas only one case (8%) harbored TP53 muta-
tion (R273C). Concurrently, TP53 mutations were present in 
104 of the 218 remaining TCGA cases (48%), confirming the 
significant difference in TP53 mutations between mucinous 
and nonmucinous tumors (p = 0.007).
Interestingly, we observed in the TCGA data set that the 
overall mutational burden was lower in mucinous tumors versus 
nonmucinous tumors (p = 0.0099; Fig. 3A). TP53-mutant cases 
showed a higher mutation count, suggesting that the low muta-
tion burden in mucinous tumors may be associated with a lack 
of TP53 mutations (Figs. 3B and 4). Because never smokers 
also harbored a lower mutation burden (Fig. 3C), possibly due 
to the reduced exposure to chronic DNA damage, we performed 
multivariate analysis which revealed that TP53 status likely 
contributed to the low mutation burden in mucinous tumors 
(Supplementary Table 7, Supplemental Digital Content, http://
links.lww.com/JTO/A842). The smoking status, although an 
independent factor for the mutation burden, was not a signifi-
cant confounding factor for the low mutation burden observed 
in mucinous tumors (Supplementary Table 7, Supplemental 
Digital Content, http://links.lww.com/JTO/A842).
Survival analysis was performed in our cohort 
patients with clinical data available and limited to those who 
FIGURE 2.  Pie charts showing the fraction of mucinous adenocarcinomas that harbor the indicated drivers (A) and the fraction 
of subtypes of KRAS mutations (B).
FIGURE 3.  Scatter dot plots for total mutation 
count between two groups defined by mucinous 
histology (A), TP53 mutation (B), and smoking sta-
tus (C) in TCGA lung adenocarcinoma. TCGA, The 
Cancer Genome Atlas.
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underwent complete surgical resection for stage I to IIIA 
disease (79 patients diagnosed as invasive mucinous adeno-
carcinoma compared with 269 control patients diagnosed as 
invasive nonmucinous adenocarcinoma; Supplementary Fig. 
1, Supplemental Digital Content, http://links.lww.com/JTO/
A842). As expected, there was clear stratification in the cohort 
between stages I, II, and III for overall (all-cause mortality) 
survival and recurrence-free survival (Supplementary Fig. 7, 
Supplemental Digital Content, http://links.lww.com/JTO/
A842; p < 0.001). When comparing patients with mucinous 
versus nonmucinous adenocarcinoma, there was no statisti-
cally significant difference in overall survival when combin-
ing all stages (Fig. 5A; p = 0.499). The overall 5-year survival 
rates for patients with mucinous and nonmucinous adenocar-
cinoma were 71.7% and 67.2%, respectively, and there was no 
statistically significant difference. Because we did not have 
access to disease-specific mortality data, we instead performed 
recurrence-free survival analysis that showed a tendency for 
the mucinous cohort associating with better recurrence-free 
survival, although it did not reach statistical significance 
(Fig. 5B; p = 0.313). When examining stage-specific sur-
vival (stage I only), there were also no significant differences 
in all-cause overall (p = 0.627) and recurrence-free survival 
(p = 0.159) between the two cohorts (Supplementary Fig. 8A, 
B, Supplemental Digital Content, http://links.lww.com/JTO/
A842), although once again patients with mucinous tumor 
showed a tendency to have better recurrence-free survival. In 
patients with mucinous adenocarcinoma, there were no dif-
ferences in prognosis according to the status of KRAS muta-
tions or gene fusions (p = 0.552 and 0.848, respectively). Of 
79 patients with the mucinous type, 14 patients (17.7%) had 
disease recurrence that was limited to the lungs. No patients 
with recurrent disease had extrapulmonary recurrence. By 
contrast, of 192 stage I patients with the nonmucinous type, 
38 patients (19.8%) had recurrence of disease; the recurrence 
sites for 13 patients (34.2%) were limited to the lungs, but 25 
patients (65.8%) presented with at least one extrapulmonary 
site of metastasis.
DISCUSSION
In this study, we have shown that invasive mucinous ade-
nocarcinoma of the lung is genetically and clinically distinct. 
The tumors have a low mutation burden and most often have a 
single identifiable driver mutation. KRAS mutations were the 
FIGURE 4.  Distribution of mutation counts in TCGA 
lung adenocarcinoma. Mucinous adenocarcinomas 
(red) and TP53-mutant cases (blue) are indicated. EGFR-
mutant cases (enriched in nonsmokers), KRAS-mutant 
cases (enriched in smokers), and ALK/ROS1/RET fusions 
(enriched in nonsmokers) are included as a validation of 
the data set. TCGA, The Cancer Genome Atlas.
FIGURE 5.  Survival curves comparing mucinous and nonmucinous cases for overall (A) and recurrence-free (B) survival in stage I–IIIA.
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most frequent driver in our mucinous cohort (63%), as have 
been previously described.3,6 In terms of specific KRAS muta-
tions, G12C is most common in lung adenocarcinoma in gen-
eral, but G12D and G12V were most common in our cohort. 
G12D and G12V are most common in colorectal and pan-
creatobiliary carcinomas,20 suggesting that invasive mucinous 
adenocarcinoma of lung may have more in common with pan-
creatobiliary and intestinal tract cancers. Interestingly, pan-
creatic adenocarcinomas metastatic to the lung often exhibit 
mucinous lepidic pattern and can be difficult to differentiate 
from primary invasive mucinous adenocarcinomas of the lung 
for the pathologist.21
Following KRAS mutations, unique gene fusions were the 
next most common drivers. Three groups have recently reported 
CD74-NRG1 fusions in invasive mucinous adenocarcinoma of 
the lung.10–12 CD74-NRG1 fusion protein activates ERBB3 
and the PI3K-AKT signaling pathway through ERBB2 and 
ERBB3 dimerization.10 Thus, patients with CD74-NRG1 rear-
ranged lung cancers may be treated by blocking ligand-receptor 
interactions or by inhibition of ERBB receptors. We identi-
fied another NRG1 fusion with a novel partner, VAMP2-NRG1 
fusion. Vesicle-associated membrane protein is involved in the 
docking and fusion of synaptic vesicles. The epidermal growth 
factor like domain of NRG1 was preserved in this fusion pro-
tein. We also identified a TRIM4-BRAF fusion. TRIM24-BRAF 
fusion has been recently described in invasive mucinous adeno-
carcinoma of the lung11; however, to our knowledge, TRIM4 is a 
novel partner for BRAF in all cancers. Previous studies indicate 
that patients with cancer harboring BRAF fusion can be treated 
with RAF or MEK inhibitors.22,23 We could not find CD74-
NRG1 or other BRAF fusions in another cohort of 192 cases, 
suggesting their specificity for invasive mucinous adenocarci-
noma (data not shown). The MPRIP-NTRK1 and CD74-NTRK1 
fusions have previously been identified in lung adenocarci-
noma.24 The TPM3-NTRK1 fusion was reported in papillary 
thyroid carcinoma and colorectal adenocarcinoma, but the case 
in our cohort describes the first TPM3-NTRK1 fusion in lung 
cancer.25,26 Given that the prior success of treatment with kinase 
inhibitors in patients with cancers harboring ALK and ROS1 
fusions, NTRK1 fusions can also be a therapeutic target to selec-
tive NTRK1 inhibitors.24 Nakaoku et al.11 identified a ERBB4 
fusion in their cohort, but none were identified in our cohort. 
Thus, this may be due to low frequency of ERBB4 fusion.
We found that TP53 mutations are rare in invasive 
mucinous adenocarcinomas, with a TP53 mutation identi-
fied in only two out of the 50 cases examined. We hypoth-
esize that the lack of TP53 mutations may explain in part why 
invasive mucinous adenocarcinomas (even those arising in 
smokers) have a lower mutational burden than nonmucinous 
tumors. Lung adenocarcinomas in general have one of the 
highest mutational burdens of any tumor types, likely due to 
chronic DNA damage resulting from smoking. Our data sug-
gest that not smoking but rather the TP53 status may be the 
main contributor to the mutation burden in invasive mucinous 
adenocarcinomas that seem to be genetically simple with one 
principal driver. If there is indeed dependence on one driver, 
one might expect these tumors to respond well to agents that 
target the driver. We have anecdotal evidence of complete and 
durable responses to crizotinib from two invasive mucinous 
adenocarcinomas. This includes one with an ALK fusion and a 
second with an ROS1 fusion.
Survival data for invasive mucinous adenocarcinoma 
have been limited due to its low incidence, and the results of 
the few published reports have been conflicting.7,8 The most 
recent reports of lung adenocarcinomas classified in accor-
dance with the IASLC/ATS/ERS classification scheme have 
excluded invasive mucinous adenocarcinomas from survival 
analysis because their number is limited and the IASLC/ATS/
ERS classification recommended that patients with variant 
subtypes be separated from those with conventional invasive 
adenocarcinoma.8,27 Yoshizawa et al.7 reported recurrence-free 
survival of 514 stage I cases including 13 invasive mucinous 
adenocarcinomas. They classified invasive mucinous adeno-
carcinoma in the high grade group based on a high incidence 
of recurrence. In our study, however, there was no significant 
difference in recurrence-free survival between invasive muci-
nous adenocarcinoma and the others, even though mucinous 
adenocarcinoma showed a tendency for better recurrence-
free survival. Interestingly, all recurrences were limited to 
the lungs without extrapulmonary metastases in our invasive 
mucinous adenocarcinoma cohort. This finding suggests that 
invasive mucinous adenocarcinomas may not be aggressive 
tumors.
CONCLUSION
In conclusion, our data suggest that invasive mucinous 
adenocarcinoma is typified by (1) frequent KRAS mutations 
and a growing list of gene fusions, but rare TP53 mutations, 
(2) a low mutation burden overall, and (3) a recurrence-free 
survival that is at least as long as nonmucinous tumors, with 
recurrences limited to the lungs. Invasive mucinous adenocar-
cinoma of the lung is a disease that, due to its apparently lim-
ited number of associated driver mutations, may be expected 
to show durable responses to targeted agents.
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